-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on AbbVie, Lowers Price Target to $235

Benzinga·11/03/2025 20:08:03
Listen to the news
Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.